Hydroxyethyl starch - Can the safety problems be ignored?

Wiener Klinische Wochenschrift

Volumn 116, Issue 17-18, 2004, Pages 640-641

  Boldt, Joachim ^a  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HETASTARCH;

ANAPHYLAXIS; BLEEDING; CEREBROVASCULAR DISEASE; CRITICAL ILLNESS; DRUG SAFETY; HUMAN; HYPOVOLEMIA; LETTER;

ANAPHYLAXIS; BLOOD COAGULATION DISORDERS; BLOOD SUBSTITUTES; CONFIDENCE INTERVALS; HEMORRHAGE; HETASTARCH; HUMANS; INCIDENCE; KIDNEY; META-ANALYSIS; PRURITUS; RISK FACTORS; SAFETY;

EID: 5344220932     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-004-0235-5     Document Type: Letter

References (17)

1. Wiedermann CJ (2004) Hydroxyethyl starch - can the safety problems be ignored? Wien Klin Wochenschr 116: 583-594
2. Rudolf J (2002) Hydroxyethyl starch for hypervolemic hemodilution in patients with acute ischemic stroke: a randomized, placebo-controlled phase II safety study. Cerebrovasc Dis 14: 33-41
3. Grauer MT, Baus D, Woessner R, Bepperling F, Kahles T, Georgi S, et al (2001) Effects on general safety and coagulation after long-term, high-dose volume therapy with 6% hydroxyethyl starch 130/0.4 in patients with acute ischemic stroke. Results of a randomized, placebo-controlled, double-blind study. Crit Care 5 [Suppl 1]: S53-54
4. Woessner R, Grauer MT, Dieterich HJ, Bepperling F, Baus D, Kahles T, Georgi S, Bianchi O, Morgenthaler M, Treib J (2003) Influence of a long-term, high-dose volume therapy with 6% hydroxyethyl starch 130/0.4 or crystalloid solution on hemodynamics, rheology and hemostasis in patients with acute ischemic stroke. Results of a randomized, placebo-controlled, double-blind study. Pathophysiol Haemost Thromb 33: 121-126
5. Barron ME, Wilkes MM, Navickis RJ (2004) A systematic review of the comparative safety of colloids. Arch Surg 139: 552-563
6. Laxenaire MC, Charpentier C, Feldman L (1994) Reactions anaphylactoides aux subitutes colloidaux du plasma: incidence, facteurs de risque, mecanismes. Ann Fr Anest Reanimat 13: 301-310
7. Ring J, Messmer K (1977) Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet 1: 466-469
8. Jungheinrich C, Sauermann W, Bepperling F, Vogt NH (2004) Volume efficacy and reduced influence on measures of coagulation using hydroxyethyl starch 130/0.4 (6%) with an optimised in vivo molecular weight in orthopaedic surgery: a randomised, double-blind study. Drugs RD 5: 1-9
9. Leuschner J, Opitz J, Winkler A, Scharpf R, Bepperling F (2003) Tissue storage of 14C-labelled hydroxyethyl starch (HES) 130/0.4 and HES 200/0.5 after repeated intravenous administration to rats. Drugs RD 4: 331-338
10. Waitzinger J, Bepperling F, Pabst G, Opitz J (2003) Hydroxyethyl starch (HES) [130/0.4], a new HES specification: pharmacokinetics and safety after multiple infusions of 10% solution in healthy volunteers. Drugs RD 4: 149-157
11. Jungheinrich C, Scharpf R, Wargenau M, Bepperling F, Baron JF (2002) The pharmacokinetics and tolerability of an intravenous infusion of the new hydroxyethyl starch 130/0.4 (6%, 500 mL) in mild-to-severe renal impairment. Anesth Analg 95: 544-551
12. Asskali F, Forster H (1999) The accumulation of different substituted hydroxyethyl starches (HES) following repeated infusions in healthy volunteers. Anasthesiol Intensivmed Notfallmed Schmerzther 34: 537-541
13. Neff TA, Doelberg M, Jungheinrich C, Sauerland A, Spahn DR, Stocker R (2003) Repetitive large-dose infusion of the novel hydroxyethyl starch 130/0.4 in patients with severe head injury. Anesth Analg 96: 1453-1459
14. Jonville-Bera AP, Autret-Leca E, Gruel Y (2001) Acquired type I von Willebrand's disease associated with highly substituted hydroxyethyl starch. N Engl J Med 345: 622-623
15. Gallandat Huet RCG, Siemens AW, Baus D, van Rooyen-Butijn WT, Haagenaars JAM, van Oeveren W, et al (2000) A novel hydroxyethyl starch (Voluven®) for effective perioperative plasma volume substitution in cardiac surgery. Can J Anesth 47: 1207-1215
16. Längeren O, Doelberg M, Ang ET, Bonnet F, Capdevila X, Coriat P (2001) Voluven, a lower substituted novel hydroxyethyl starch (HES 130/0.4), causes fewer effects on coagulation in major orthopedic surgery than HES 200/0.5. Anesth Analg 92: 855-862
17. Wilkes MM, Navickis RJ, Sibbald WJ (2001) Albumin versus hydroxyethyl starch in cardiopulmonary bypass surgery: a meta-analysis of postoperative bleeding. Ann Thorac Surg 72: 527-533